|Day's Range||38.57 - 39.30|
|52 Week Range||30.80 - 55.95|
|PE Ratio (TTM)||-21.29|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Regeneron Pharmaceuticals, Inc. (REGN) presented positive phase II data, evaluating its investigational angiopoietin-like 3 (ANGPTL3) antibody, evinacumab at the National Lipid Association's (NLA) Scientific Sessions.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to The Medicines Co. Here are 5 ETFs with the largest exposure to MDCO-US. Comparing the performance and risk of The Medicines Co. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
You probably haven’t heard of Alex Denner‘s Sarissa Capital Management, which is a shame, as the fund is coming off a first-quarter in which its stock picks in companies valued at $1 billion or more delivered weighted average returns of 53.2%, pushing its 1-year returns to an even 200%. With the media paying most of […]